PANEL LINEUP - PHARMA FUTURES
PETIT AMPITHEATER 12:35-13:35
Do France’s strong hemp and pharmaceutical industries give it a competitive edge in medical cannabis production?
Is greater collaboration between international medical cannabis producers and the pharmaceutical giants in Europe needed to further legitimise the development of the industry?
How will biosynthesis impact the production of cannabinoid medicines?
What are the benefits of full spectrum products versus extracts/isolated compound products?
To what extent are patents applicable to phytocannabinoids?
CHAIR: Sofia Sanz
With more than 10 years expertise in the healthcare Industry, Sofia Sanz worked as Business Development & Sales Manager at Alcaliber, a world leading company in the production of specialised APIs and controlled substances - NRMs for the pharmaceutical industry. Sofia primarily focused on the expansion of the business worldwide opening markets, acquiring new customers and strengthening partnerships internationally across territories from North America, LATAM to EMEA and Asia.
Alex is CEO and founder of Senzer, a world leader in inhaled pharmaceutical cannabinoids. Currently Alex oversees FDA clinical programmes for Senzer’s lead products that target chemotherapy side effects and is readying to launch its prescription portfolio in the UK and EU in 2019.
Alex invented the respiratory technology 12 years ago and holds over 400 internationally granted patents. He is also founder and non-executive director of Kind Consumer Holdings, where he developed the first and only MHRA-approved smoking cessation device, Voke®.
Tjalling Erkelens is the co-founder and CEO of Bedrocan, the sole supplier of medical cannabis to the Dutch Office for Medicinal Cannabis. Educated as a teacher and journalist, Tjalling started a horticultural company with brother-in-law Freerk Bruining. In 1992 the group grew their first cannabis crop for seed production. Today, Bedrocan is a leading and world renowned European cannabis company.
Jason Moscovici is a Lawyer and Biochemist with the firm ROBIC, in Montreal, Canada. His legal and scientific background allows him to counsel clients on both counts; notably with respect to trademarks, patents, copyrights, industrial designs, licences, trade secrets, and plant breeder’s rights.
Jason is a trusted legal advisor to the Canadian cannabis industry and is often asked to give talks and provide opinions on the many hurdles and opportunities that the stakeholders in this industry face. Jason sits on the life sciences committee of ROBIC, and spearheads the cannabis group of the firm.
Nastasia Bach is a consultant at Pivot Regulatory, a Munich-based consultancy specialised in regulation in the healthcare sector. Nastasia’s expertise lie in the German medical cannabis market. She advises on political advocacy and the regulation of prescriptions, reimbursement, pricing and the tender. Nastasia has a background in law and politics and holds a Master of Law from the University of Cambridge.